(Q46705148)

English

Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status

scientific article published on 14 November 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status (English)

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Atsushi Shikina

1

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Eiji Shinto

2

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Yojiro Hashiguchi

3

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Hideki Ueno

4

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Yoshihisa Naito

5

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Koichi Okamoto

6

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Toru Kubo

7

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Satomi Fukazawa

8

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Junji Yamamoto

9

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Kazuo Hase

10

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

publication date

14 November 2013

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Japanese Journal of Clinical Oncology

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

44

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

1

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

42-48

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

Stem cells, cancer, and cancer stem cells

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Tumour stem cells and drug resistance

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Biological and genetic characteristics of tumor-initiating cells in colon cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

CD133 expression is an independent prognostic marker for low survival in colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Identification and expansion of human colon-cancer-initiating cells

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

CD133 expression predicts for non-response to chemotherapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Estimates of the worldwide mortality from 25 cancers in 1990.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT168

21 January 2018

Identifiers

10.1093/JJCO/HYT168

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

release_mnce3vsrf5hhfatowul6gb6ucm

1 reference

https://api.fatcat.wiki/v0/release/mnce3vsrf5hhfatowul6gb6ucm

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/24244031

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46705148&oldid=2127625461"